With SGLT2 inhibitors, HF patients had reduced mortality risks (RR 0.89, 95% CI 0.80–0.99, I2 = 0), and non-HF patients had lower risks of major adverse CV events (RR 0.92, 95% CI 0.85–0.99, I2 = 0). This evidence concerns the gene SLC5A2 and hydrops fetalis.